Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension.
Lattanzi B, Gioia S, Di Cola S, D'Ambrosio D, Nardelli S, Tavano D, Farcomeni A, Merli M, Riggio O. Lattanzi B, et al. Among authors: d ambrosio d. Liver Int. 2019 Oct;39(10):1937-1942. doi: 10.1111/liv.14160. Epub 2019 Jun 26. Liver Int. 2019. PMID: 31152475
Weight Gain and De Novo Metabolic Disorders after Liver Transplantation.
Lattanzi B, D'Ambrosio D, Tavano D, Pitoni D, Mennini G, Ginanni Corradini S, Rossi M, Merli M. Lattanzi B, et al. Among authors: d ambrosio d. Nutrients. 2019 Dec 10;11(12):3015. doi: 10.3390/nu11123015. Nutrients. 2019. PMID: 31835505 Free PMC article.
The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease.
Lattanzi B, Nardelli S, Pigliacelli A, Di Cola S, Farcomeni A, D'Ambrosio D, Gioia S, Ginanni Corradini S, Lucidi C, Mennini G, Rossi M, Merli M, Riggio O. Lattanzi B, et al. Among authors: d ambrosio d. Dig Liver Dis. 2019 Nov;51(11):1508-1512. doi: 10.1016/j.dld.2019.09.004. Epub 2019 Oct 7. Dig Liver Dis. 2019. PMID: 31601536
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
Scaldaferri F, D'Ambrosio D, Holleran G, Poscia A, Petito V, Lopetuso L, Graziani C, Laterza L, Pistone MT, Pecere S, Currò D, Gaetani E, Armuzzi A, Papa A, Cammarota G, Gasbarrini A. Scaldaferri F, et al. Among authors: d ambrosio d. PLoS One. 2017 Oct 26;12(10):e0186575. doi: 10.1371/journal.pone.0186575. eCollection 2017. PLoS One. 2017. PMID: 29073159 Free PMC article.